![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Medicenna Therapeutics Corporation | NASDAQ:MDNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.157 | 0.1565 | 0.1612 | 0 | 01:00:00 |
April 22, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
United States of America
Re: | Medicenna Therapeutics Inc. |
Application for Withdrawal | |
Post-Effective Amendment No. 1 to Form F-3 (File No. 333-269868) | |
Filed April 16, 2024 under EDGAR code F-3/A |
Ladies and Gentlemen:
In accordance with Rule 477(a) under the Securities Act of 1933, as amended, and as requested by the staff of the Securities and Exchange Commission (the “SEC Staff”), Medicenna Therapeutics Inc. (the “Company”) hereby respectfully requests the withdrawal of its post-effective amendment no. 1 to Form F-3 (File No. 333-269868) filed on April 16, 2024 because it was inadvertently filed under the incorrect EDGAR code for pre-effective amendments, “F-3/A”, rather than “POS AM”.
As requested by the SEC Staff, post-effective amendment no. 1 to the Form F-3 will be re-filed under the correct EDGAR code.
If you have any questions or require further information, please do not hesitate to contact Thomas Rose of Troutman Pepper Hamilton Sanders LLP, the Company’s outside counsel, at (757) 687-7715.
Sincerely,
Medicenna Therapeutics Inc.
/s/ David Hyman
David Hyman
Chief Financial Officer
1 Year Medicenna Therapeutics Chart |
1 Month Medicenna Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions